Lv54
1120 积分 2026-03-18 加入
The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron
13天前
已完结
Is biased agonism helpful in the treatment of obesity with the GLP-1 receptor analogues?
20天前
已关闭
Dissociable hindbrain GLP1R circuits for satiety and aversion
20天前
已完结
Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes
20天前
已完结
Perceptions, attitudes and barriers to effective obesity care among people living with obesity and healthcare professionals in China: The ACTION‐China study
27天前
已完结
Attitudes towards therapeutic options for weight management, including weight loss medications and surgery, among people living with obesity and healthcare professionals in China: A secondary analysis from the ACTION ‐China study
27天前
已完结
[Current status and management of obesity in China]
28天前
已完结
Prevalence and Treatment of Diabetes in China, 2013-2018
28天前
已完结
Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide
1个月前
已完结
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
1个月前
已完结
皖公网安备34019202002308
